FIELD: pharmacology.SUBSTANCE: invention relates to new crystalline forms of sodium salt or sodium salt monohydrate of a compound of the general formula (AA). The compound has inhibitory activity against HIV integrase. The AA compound corresponds to the following structural formula:.The crystalline form of the sodium salt of the AA compound has (a) characteristic diffraction peaks at 2-theta angles of 6.4±0.2° 9.2±0.2° 13.8°±0.2° 19.2±0.2° and 21.8°±0.2°, in the X-ray powder diffraction pattern and/or (b) the characteristic infrared absorption spectra at 1641 cm-1 ± 2 cm-1, 1536 cm-1 ± 2 cm-1, 1503 cm-1 ± 2 cm-1 and 1424 cm-1 ± 2 cm-1 and/or (c) 13C-NMR spectra in the solid state, substantially as shown in Fig. 3. The crystalline form of the sodium salt monohydrate of the AA compound has (d) characteristic diffraction peaks at 2-theta angles equal to 8.0°±0.2° 9.3°±0.2° 11.3°±0.2° 16.0°±0.2° and 22.8°±0.2°, in the X-ray powder diffraction pattern and/or (e) characteristic infrared absorption spectra at 1637 cm-1 ± 2 cm-1, 1536 cm-1 ± 2 cm-1, 1501 cm-1 ± 2 cm-1 and 1422 cm-1 ± 2 cm-1 and has substantially X-ray diffraction patterns, as shown in Fig. 4. The invention also relates to a pharmaceutical composition comprising the said crystalline forms, as well as to a process for preparation of the crystalline form of the sodium salt monohydrate of the AA compound. The method includes stages: a) dissolution of the sodium salt compounds of the formula (AA) in a solution of THF (tetrahydrofuran)-water, b) addition of aqueous NaOH to the obtained solution, c) stirring of the obtained mixture, d) filtering of the obtained sediment, washing it with a THF solution - water and THF and drying.EFFECT: crystalline forms of the sodium salt and its monohydrate show high solubility in water or saline, have high bioavailability, increased stability to heat and light, and simplify compound application.13 cl, 7 dwg, 3 exИзобретение относится к новым кристаллическим формам натриевой соли
